Renal FunctionNCT07059559
Rhythmic Walking Program and Renal Function and Oxidative Stress
A study testing Rhythmic walking in people with Renal Function, run by Burapha University at 1 site in Thailand.
Trial summary
This study designed a over-knee automatic step counter device. Then, we evaluated its efficacy on renal function and oxidative stress in patients with chronic kidney disease. Read more about this study
- Who is it for?
- Ages 18 to 59 years
- Conditions the study is for
- Renal Function
- What is being tested?
- Rhythmic walking
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 1 siteThailand
- Study dates
- 17 Jul 2024to 1 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 59 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male or female
- Aged between 18 and 59 years
- Diagnosed by a physician with chronic kidney disease stage 2-4, with a glomerular filtration rate (GFR) between 15-89 milliliters per minute, persisting for at least 3 months
Who cannot join
- No musculoskeletal disorders that hinder walking, such as osteoarthritis
- Not engaging in regular exercise (less than 3 times per week or less than 150 minutes per week)
- Not regularly taking medications or supplements containing antioxidants
Trial locations and contacts
1 site in 1 country.
Thailand1 site
Rehabilitation Medicine Department, Chamni Hospital
Chamni, Changwat Buri Ram, 31110
About this study
Official title: Efficacy of Rhythmic Walking Program on Renal Function and Oxidative Stress in Subjects With Chronic Kidney Disease
This study designed a over-knee automatic step counter device. Then, we evaluated its efficacy on renal function and oxidative stress in patients with chronic kidney disease.
Read the detailed description
This study is a randomized controlled trial. Patients who consent to participate and pass the screening process will be randomly assigned to groups based on the order of their participation (random by sequence). Patients who join in odd-numbered order, such as 1st, 3rd, 5th, etc., will receive standard care as provided by the hospital (control group). Patients who join in even-numbered order, such as 2nd, 4th, 6th, etc., will receive a walking program. This involves continuous walking exercise for 30 minutes, once a day, three days a week, over a period of three months. During the walking sessions, patients will walk at a pace of 60 steps per minute, or one step per second.
- Conditions
- Renal Function
- Being tested
- Rhythmic walking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rhythmic walkingOther
Patients who consent to participate and pass the screening process were randomly assigned to groups based on the order of their participation (random by sequence): control group or rhythmic walking group.
| Study group | Role | What they receive |
|---|---|---|
| Control group | No intervention | Patients who join in odd-numbered order, such as 1st, 3rd, 5th, etc., will receive standard care as provided by the hospital (control group). |
| Rhythmic walking group | Experimental | Patients who join in even-numbered order, such as 2nd, 4th, 6th, etc., will receive a walking program. This involves continuous walking exercise for 30 minutes, once a day, three days a week, over a period of three months. During the walking sessions, patients will walk at a pace of 60 steps per minute, or one step per second. Receives: Other: Rhythmic walking |
What is being measured
The primary outcome is the main question the study is designed to answer.
Creatinine level
Blood creatinine level was measured in mg/dL unit
Measured: Day 0 and day 91
Malondialdehyde level
Blood malondialdehyde level was measured in micromolar unit
Measured: Day 0 and day 91
Superoxide dismutase activity level
Blood superoxide dismutase activity level was measured in percent unit
Measured: Day 0 and day 91
Estimated glomerular filtration rate level
Estimated glomerular filtration rate level was measured in ml/min/1.73 m2 unit
Measured: Day 0 and day 91
Estimated creatinine clearance level
Estimated creatinine clearance level was measured in ml/min unit
Measured: Day 0 and day 91
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2025
- Study start17 Jul 2024
- Primary completion1 Jul 2025
- Study completion1 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal FunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a randomized controlled trial. Patients who consent to participate and pass the screening process will be randomly assigned to groups based on the order of their participation (random by sequence). Patients who join in odd-numbered order, such as 1st, 3rd, 5th, etc., will receive standard care as provided by the hospital (control group). Patients who join in even-numbered order, such as 2nd, 4th, 6th, etc., will receive a walking program.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Burapha University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Piyapong Prasertsri, Burapha University
- Investigators
- Piyapong Prasertsri, Ph.D., Principal investigator, Faculty of Allied Health Sciences, Burapha University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07059559
- Sponsor's protocol ID
- BRO 2024-074
- Status last verified
- Jul 2025
- First submitted
- 1 Jul 2025
- Last updated
- 11 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to make individual participant data (IPD) available to other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Rhythmic Walking Program on Renal Function and Oxidative Stress in Subjects With Chronic Kidney Disease
- ClinicalTrials.gov ID
- NCT07059559
- Acronym / sponsor ID
- BRO 2024-074
- Conditions
- Renal Function
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Burapha UniversityUniversity, hospital or other
- Study start
- 17 Jul 2024 (actual)
- Primary completion
- 1 Jul 2025 (actual)
- Study completion
- 1 Jul 2025 (actual)
- First posted
- 11 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study designed a over-knee automatic step counter device. Then, we evaluated its efficacy on renal function and oxidative stress in patients with chronic kidney disease.
Detailed description
This study is a randomized controlled trial. Patients who consent to participate and pass the screening process will be randomly assigned to groups based on the order of their participation (random by sequence). Patients who join in odd-numbered order, such as 1st, 3rd, 5th, etc., will receive standard care as provided by the hospital (control group). Patients who join in even-numbered order, such as 2nd, 4th, 6th, etc., will receive a walking program. This involves continuous walking exercise for 30 minutes, once a day, three days a week, over a period of three months. During the walking sessions, patients will walk at a pace of 60 steps per minute, or one step per second.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- This study is a randomized controlled trial. Patients who consent to participate and pass the screening process will be randomly assigned to groups based on the order of their participation (random by sequence). Patients who join in odd-numbered order, such as 1st, 3rd, 5th, etc., will receive standard care as provided by the hospital (control group). Patients who join in even-numbered order, such as 2nd, 4th, 6th, etc., will receive a walking program.
| Arm | Type | Receives |
|---|---|---|
| Control group | No intervention | –Patients who join in odd-numbered order, such as 1st, 3rd, 5th, etc., will receive standard care as provided by the hospital (control group). |
| Rhythmic walking group | Experimental | Other: Rhythmic walkingPatients who join in even-numbered order, such as 2nd, 4th, 6th, etc., will receive a walking program. This involves continuous walking exercise for 30 minutes, once a day, three days a week, over a period of three months. During the walking sessions, patients will walk at a pace of 60 steps per minute, or one step per second. |
Who may qualify
- Ages
- 18 to 59 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Male or female
- Aged between 18 and 59 years
- Diagnosed by a physician with chronic kidney disease stage 2-4, with a glomerular filtration rate (GFR) between 15-89 milliliters per minute, persisting for at least 3 months
Key exclusion criteria (3 listed)
- No musculoskeletal disorders that hinder walking, such as osteoarthritis
- Not engaging in regular exercise (less than 3 times per week or less than 150 minutes per week)
- Not regularly taking medications or supplements containing antioxidants
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rhythmic walkingPatients who consent to participate and pass the screening process were randomly assigned to groups based on the order of their participation (random by sequence): control group or rhythmic walking group. | Other | Rhythmic walking group |
Primary outcome
Creatinine level
Time frame: Day 0 and day 91
Blood creatinine level was measured in mg/dL unit
Malondialdehyde level
Time frame: Day 0 and day 91
Blood malondialdehyde level was measured in micromolar unit
Superoxide dismutase activity level
Time frame: Day 0 and day 91
Blood superoxide dismutase activity level was measured in percent unit
Estimated glomerular filtration rate level
Time frame: Day 0 and day 91
Estimated glomerular filtration rate level was measured in ml/min/1.73 m2 unit
Estimated creatinine clearance level
Time frame: Day 0 and day 91
Estimated creatinine clearance level was measured in ml/min unit
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2025.
- Individual participant dataSharing planned: No. There is no plan to make individual participant data (IPD) available to other researchers.
Related trials for Renal Function
RecruitingObservational study
A Natural History Study of Metabolic Sizing in Health and Disease
Metabolic Disorders, Cancer
RecruitingPhase 1
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
Vasopressin Deficiency
Not yet recruiting
Effects of Increased Water Intake on Hormonal Response, Hydration Status, and Physical Function in Low-drinking Older Adults
Dehydrated, Water-Electrolyte Imbalance, Malnutrition, Dehydration (Physiology)
RecruitingPhase 1
Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function
Renal Impairment, Healthy Volunteers
RecruitingPhase 2
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Piyapong Prasertsri, Ph.D. principal investigator
Faculty of Allied Health Sciences, Burapha University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Rhythmic walking in people with Renal Function, run by Burapha University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Creatinine level (time frame: Day 0 and day 91). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2025.